Table 2. Covalent MIF inhibitors and MIF inhibitors with other structures.

Class	Compound	Structure	Activity, μM Reference(s)
phenyl-pyrimidine	4-IPP		IC50 = 0.2-0.5 [51] (TA)
isothiocyanate	BITC		IC50 = 0.79 [53] (TA)
benzoxazinone	NVS-2		IC50 = 0.020 [55] (TA); Ki = 0.027 [50] (TA); Kd = 0.055 [50] (BA)
benzoxazol-2-one	MIF098 (Alissa-5)		IC50 = 0.01 [56] (TA)
pyrimidazole	K664-1		IC50 = 0.11 [59] (TA); Ki = 45 [40] (TA), Ki = 0.16 [58] (TA)
chromene	T-614		IC50 = 6.81 [58] (TA)
	Kok-10		IC50 = 18 [60] (TA)
	Kok-17		IC50 = 6.2 [60] (TA)
isoxazoline	CPSI-2705		2-10-fold more potent than ISO-1 [35] (TA)
	CPSI-1306		100-fold more potent than ISO-1 [35] (TA)
isocoumarin	SCD-19		100% inhibition at concentration of 100 μM [37] (TA)

TA, tautomerase assay; BA, binding assay MIF-CD74k